Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00505-1
Salinas, et al. evaluate baricitinib safety with respect to VTE, MACE, and serious infection relative to TNFi in patients with RA, in routine care and observe an increased risk of VTE in patients taking baricitinib, compared to TNFi.
Venous Thromboembolism with JAK Inhibitors and Other Immune-Modulatory Drugs: a Swedish Comparative Safety Study Among Patients with Rheumatoid Arthritis
Ann Rheum Dis. 2022. doi: 10.1136/ard-2022-223050
Nationwide register-based study in Sweden finds that patients with RA treated with JAKinibs in routine clinical practice are at increased risk of venous thromboembolism (VTE), compared with those treated with bDMARDs, an increase numerically confined to pulmonary embolism.
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumaticdrugs as used against rheumatoid arthritis in clinical practice
Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keab570
Observational, nationwide cohort study finds no increased risk for cancer overall in RA patients treated with TNFis, anti-CD20 or anti-IL6.